C-RAY Achieves Breakthrough in Medical Isotope Production with China's First Fully Automated Zr-89 Process

Leveraging proprietary isotope production technology and customized automated facilities, C-Ray Therapeutics has successfully implemented China's first end-to-end automated production process for Zirconium-89 (⁸⁹Zr) – positioning itself among the few Chinese suppliers capable of stable ⁸⁹Zr provision.

Technical Background:

• Positron Emission Tomography (PET) is a rapidly advancing molecular imaging technology renowned for its high sensitivity and quantitative capabilities.

• Molecular probes are prerequisites for molecular imaging. While Fluorine-18 (¹⁸F) is widely used for its excellent imaging properties, its short half-life (t₁/₂ = 109 min) limits applications involving macromolecular bioactive agents (e.g., antibodies) that require extended imaging windows.

• Zirconium-89 (⁸⁹Zr) emerges as an ideal PET immunoimaging isotope with:
  ▶ 78.4-hour half-life (aligns with biological clearance of monoclonal antibodies)
  ▶ 0.897 MeV average positron energy
  ▶ Optimized pharmacokinetic compatibility for antibody-based tracers

Strategic Significance:
This milestone completes a critical component of Tongrui Biotech's autonomous medical isotope supply chain. Moving forward, we will provide domestic and international partners with:
✓ Consistent, controllable ⁸⁹Zr quality
✓ Full compliance with Group Standards